FrancophonIA/ELRC3.0 huggingface dataset:
English: Co-administration of ketoconazole (an inhibitor of CYP3A4 with cilostazol resulted in a 117% increase in the AUC of cilostazol, accompanied by a 15% decrease in the AUC of the dehydro metabolite and a 87% increase in the AUC of the 4`-trans-hydroxy metabolite.
Maltese: L-għoti ta' ketoconazole (inibitur ta' CYP3A4) flimkien ma' cilostazol wasslet għal żieda ta' 117% fl-AUC ta cilostazol, akkumpanjata minn tnaqqis ta' 15% fl-AUC tal-metabolit dehydro u żieda ta' 87% fl-AUC tal-metabolit 4`-trans-hydroxy.
English: Based on AUC, the overall pharmacological activity increases by 47% when co-administered with omeprazole.
Maltese: Ibbażat fuq l-AUC, l-attività farmakoloġika globali tiżdied b'47% meta jingħata flimkien ma' omeprazole.
English: Other frequent causes of discontinuation included palpitation and diarrhoea (both 1.1%).
Maltese: Kawżi frekwenti oħra ta' wara l-waqfien kienu jinkludu palpitazzjoni u dijarea (it-tnejn 1.1%).
English: Inhibitors of platelet aggregation
Maltese: Impedituri tal-aggregazzjoni tal-plejtlits
English: Chest pain, asthenia
Maltese: Uġigħ tas-sider, astenja
English: One tablet contains 100 mg cilostazol.
Maltese: Kull pillola fiha 100 mg cilostazol.
English: Patients with any known predisposition to bleeding (e.g. active peptic ulceration, recent [within six months] haemorrhagic stroke, proliferative diabetic retinopathy, poorly controlled hypertension)
Maltese: • Pazjenti b'kull predispożizzjoni magħrufa għal fsada (eż. ulċerazzjoni peptika attiva, puplesija emorraġika riċenti [fi żmien sitt xhur], retinopatija dijabetika proliferattiva, pressjoni għolja li ma hiex ikkontrollata tajjeb)
English: The antiplatelet effect may theoretically be altered and should be carefully monitored when cilostazol is co-administered with CYP3A4 and CYP2C19 inducers.
Maltese: L-effett antiplejtlit jista' teoretikament jiġi mibdul u għandu jiġi monitorjat b'attenzjoni meta cilostazol jingħata flimkien ma' indutturi ta' CYP3A4 u CYP2C19.
English: Patients with any history of ventricular tachycardia, ventricular fibrillation or multifocal ventricular ectopics, whether or not adequately treated, and in patients with prolongation of the QTc interval
Maltese: • Pazjenti bi storja ta' takikardija ventrikulari, fibrillazzjoni ventrikulari jew ektopiċi ventrikulari multifokali, kemm jekk trattati b'mod adegwat jew le, u f'pazjenti b'titwil tal-intervall QTc
English: An increase in the frequency of diarrhoea and palpitation has been found in patients older than 70 years.
Maltese: Żieda fil-frekwenza ta' dijarea u palpitazzjoni kienet osservata f'pazjenti akbar minn 70 sena.
English: The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm; in patients at risk this consequently may induce angina pectoris.
Maltese: Iż-żieda fir-rata tal-qalb assoċjata ma' cilostazol hija ta' madwar 5 sa 7 bpm; f'pazjenti f'riskju din tista' tikkawża anġina pectoris.
English: An increase in the frequency of palpitation and peripheral oedema was observed when cilostazol was combined with other vasodilators that cause reflex tachycardia e.g. dihydropyridine calcium channel blockers.
Maltese: Żieda fil-frekwenza ta' palpitazzjonijiet u edima periferali kienet osservata meta cilostazol kien kombinat ma' vażodilaturi oħra li jikkawżaw takikardja riflessiva eż. imblokkaturi talkanal tal-kalċju ta' dihydropyridine.
English: From data generated in nine placebo-controlled studies (where 1,634 patients were exposed to cilostazol), it has been demonstrated that cilostazol improves exercise capacity as judged by changes in Absolute Claudication Distance (ACD, or maximal walking distance) and Initial Claudication Distance (ICD, or pain-free walking distance) upon treadmill testing.
Maltese: Minn tagħrif iġġenerat minn 9 studji bil-plaċebo bħala kontroll (fejn 1634 pazjent kienu esposti għal cilostazol), ġie muri li cilostazol itejjeb il-kapaċità t'eżerċizzju kif iġġudikati minn bidliet fid-Distanza Assoluta ta' Klawdikazzjoni (ACD - Absolute Claudication Distance, jew distanza massima tal-mixi) u Distanza ta' Klawdikazzjoni Inizjali (ICD - Initial Caludication Distance, jew distanza ta' mixi mingħajr uġigħ) wara l-ittestjar bi treadmill.
English: For oral use Read the package leaflet before use.
Maltese: Jista' jkun li mhux il-pakketti tad-daqsijiet kollha jkunu fis-suq.
English: One tablet contains 50 mg cilostazol.
Maltese: Kull pillola fiha 50 mg cilostazol.
English: produced a reduction in triglycerides of 0.33 mmol/l (15%) and an increase in HDL-cholesterol of 0.10 mmol/l (10%).
Maltese: Wara 12-il ġimgħa, meta mqabbel ma' plaċebo, <Prodott mediċinali li fih cilostazol> 100 mg b.i.d ipproduċa tnaqqis fit-trigliċeridi ta' 0.33 mmol/l (15%) u żieda flHDL-kolesterol ta' 0.10 mmol/l (10%).
English: Musculoskeletal, connective tissue and bone disorders
Maltese: Disturbi muskolu-skeletriċi, tat-tessut konnettiv u tal-għadam
English: This corresponds to a relative improvement of 100% over placebo.
Maltese: Dan jikkorrispondi għal titjib relattiv ta' 100% fuq il-plaċebo.
English: In subjects with severe renal impairment, the free fraction of cilostazol was 27% higher and both Cmax and AUC were 29% and 39% lower respectively than in subjects with normal renal function.
Maltese: F'individwi b'indeboliment renali sever, l-frazzjoni libera ta' cilostazol kienet ta' 27% ogħla u kemm Cmax u l-AUC kienu 29% u 39% inqas rispettivament milli f'individwi b'funzjoni renali normali.Is-Cmax u l-AUC tal-metabolit dehydro kienu 41% u 47% inqas rispettivament f'individwi b'indeboliment sever tal-kliewi meta mqabbel ma' individwi b'funzjoni renali normali.Is-Cmax u l-AUC ta' 4'-trans-hydroxy cilostazol kienu 173% u 209% ogħla f'individwi b'indeboliment renali sever.
English: The signs and symptoms can be anticipated to be severe headache, diarrhoea, tachycardia and possibly cardiac arrhythmias.
Maltese: Is-sinjali u s-sintomi jistgħu jiġu antiċipati li jkunu uġigħ ta' ras, dijarea, takikardija u possibilment arritmija kardijaka.
English: Concomitant administration of cilostazol and clopidogrel did not have any effect on platelet count, prothrombin time (PT) or activated partial thromboplastin time (aPTT).
Maltese: L-għoti flimkien ta' clopidogrel u cilostazol ma kelliex effett fuq l-għadd ta' plejtlits, il-ħin ta' protrombin (PT - prothrombin time) jew il-ħin ta' parzjalment attivat ta' tromboplastin (aPTT - activated partial thromboplastin time).
English: White, round, flat faced tablets debossed with “OG30” on one side.
Maltese: Pilloli bojod, tondi, b'uċuħ ċatti li fuqhom hemm imnaqqax “OG30” fuq naħa waħda.
English: These medicines include:
Maltese: Kategorija farmakoterapewtika:
English: Based on these data, the recommended dose of cilostazol is 50 mg bid in the presence of erythromycin and similar agents (e.g., clarithromycin).
Maltese: Ibbażat fuq din id-dejta, id-doża rrakkomandata ta' cilostazol hija ta' 50 mg bid fil-preżenza ta' erythromycin u sustanzi simili (eż. clarithromycin).
English: Administration of cilostazol with diltiazem (a weak inhibitor of CYP3A4) resulted in an increase in the AUC of cilostazol of 44%, accompanied by a 4% increase in AUC of the dehydro metabolite and a 43% increase in the AUC of the 4`-trans-hydroxy metabolite.
Maltese: L-għoti ta' cilostazol ma' diltiazem (inibitur dgħajjef ta' CYP3A4)irriżulta f'żieda fl-AUC ta' cilostazol ta' 44% flimkien ma' żieda ta' 4% fl-AUC tal-metabolit 4`-trans-hydroxy.
English: Clopidogrel and other antiplatelet drugs
Maltese: Clopidogrel u mediċini oħra li jaġixxu kontra l-plejtlits
English: Refer to sections 4.3 and 4.5 for further information on bleeding risks.
Maltese: Irreferi għal sezzjonijiet 4.3 u 4.5 għal tagħrif ulterjuri dwar riskji ta' fsada.
English: The inhibition is effective against a range of aggregants (including shear stress, arachidonic acid, collagen, ADP and adrenaline); in man the inhibition lasts for up to 12 hours, and on cessation of administration of cilostazol recovery of aggregation occurred within 48-96 hours, without rebound hyperaggregability.
Maltese: Studji fl-annimali u fil-bniedem (in vivo u ex vivo) urew li cilostazol jikkawża inibizzjoni riversibbli tal-aggregazzjoni tal-plejtlits.L-inibizzjoni huwa effettiv kontra firxa ta' aggreganti (li jinkludu shear stress, arachidonic acid, kollaġen, ADP u adrenalina); fil-bniedem linibizzjoni ddum sa 12-il siegħa, u mal-waqfien tal-għoti ta' cilostazol l-irkupru t'aggregazzjoni seħħ fi żmien 48-96 siegħa, mingħajr rebound hyperaggregability.
English: The pharmacokinetics of cilostazol and its metabolites were not significantly affected by age or gender in healthy subjects aged between 50-80 years.
Maltese: Il-farmakokinetika ta' cilostazol u l-metaboliti tiegħu ma kinux affettwati b'mod sinifikanti minn età jew ġeneru sesswali f'individwi b'saħħithom ta' età bejn 50-80 sena.
English: A clinically relevant effect on cilostazol is still possible at higher quantities of grapefruit juice.
Maltese: Effett klinikament rilevanti fuq cilostazol xorta huwa possibbli bi kwantitajiet ogħla ta' meraq tal-grejpfrut.
English: Patients who may be at increased risk for serious cardiac adverse events as a result of increased heart rate, e.g. patients with stable coronary disease, should be closely monitored during treatment with cilostazol, while the use of cilostazol in patients with unstable angina pectoris, or myocardial infarction/coronary intervention within the last 6 months, or a history of severe tachyarrhythmia is contraindicated (see section 4.3).
Maltese: Pazjenti li jista' jkollhom riskju akbar ta' avvenimenti avversi serji tal-qalb bħala riżultat ta' żieda fir-rata tal-qalb, eż. pazjenti b'mard stabbli tal-koronarji, għandhom jiġu ssorveljati b'attenzjoni waqt kura b'cilostazol, waqt li l-użu ta' cilostazol huwa kontraindikat f'pazjenti b'anġina pectoris instabbli, jew b'infart mijokaridjaku/intervent fil-koronarji fl-aħħar 6 xhur, jew bi storja medika ta' takiarritmija severa (ara sezzjoni 4.3).
English: Short term (4 days) co-administration of ASA with cilostazol suggested a 23-25% increase in inhibition of ADP-induced ex vivo platelet aggregation when compared to ASA alone.
Maltese: L-għoti għal żmien qasir (4 ijiem) ta' ASA flimkien ma' cilostazol tissuġerixxi żieda ta' 2325% fl-inibizzjoni ta' ADP-indott ex vivo t'aggregazzjoni ta' plejtlits meta mqabbel ma' ASA waħedha.
English: The frequencies correspond with: Very common (≥1/10) Common (≥1/100 to <1/10) Uncommon (≥1/1,000 to <1/100) Rare
Maltese: (≥1/10,000 sa <1/1000) Rari ħafna (<1/10,000), mhux magħruf (ma jistax jiġi stmat mit-tagħrif disponibbli)
English: A meta-analysis based on weighted mean differences across the nine studies indicated that there was a significant absolute overall post-baseline improvement of 42 m in maximal walking distance (ACD) for cilostazol 100 mg b.i.d.
Maltese: Meta-analiżi bbażata fuq id-differenzi medji peżati madwar id-disa' studji indikaw li kien hemm titjib globali sinifikanti assolut wara l-linja ta' riferiment ta' 42 m f'distanza massima ta' mixi (ACD) għal cilostazol 100 mg b.i.d, fuq it-titjib li deher taħt il-plaċebo.
English: Cilostazol-containing medicinal products (see Annex I) 50 mg tablets Cilostazol-containing medicinal products (see Annex I) 100 mg tablets Cilostazol [See Annex I - To be completed nationally]
Maltese: Prodott mediċinali li fih cilostazol (ara Anness I) 50 mg pilloli Prodott mediċinali li fih cilostazol (ara Anness I) 100 mg pilloli Cilostazol [Ara Anness I - Biex timtela mill-pajjiż partikolari]
English: NAME OF THE MEDICINAL PRODUCT Cilostazol-containing medicinal products (see Annex I) 50 mg tablets Cilostazol-containing medicinal products (see Annex I) 100 mg tablets [See Annex I - To be completed nationally] Cilostazol
Maltese: Prodott mediċinali li fih cilostazol (ara Anness I) 50 mg pilloli Prodott mediċinali li fih cilostazol (ara Anness I) 100 mg pilloli [Ara Anness I - Biex timtela mill-pajjiż partikolari] Cilostazol
English: In a single-dose clinical study, no inhibition of the metabolism of warfarin or an effect on the coagulation parameters (PT, aPTT, bleeding time) was observed.
Maltese: Fi studju kliniku ta' doża waħda, ma ġiet osservata l-ebda inibizzjoni għall-metaboliżmu ta' warfarin jew xi effett fuq il-parametri ta' koagulazzjoni (PT, aPTT, ħin ta' emorraġija).
English: Renal failure, renal impairment
Maltese: Falliment tal-kliewi, indeboliment tal kliewi
English: Caution is advised when cilostazol is co-administered with CYP3A4 substrates with a narrow therapeutic index (e.g., cisapride, halofantrine, pimozide, ergot derivates).
Maltese: Kawtela hija rakkomandata meta cilostazol jingħata flimkien ma' sottostrati ta' CYP3A4 b'indiċi terapewtiku dejjaq (eż., cisapride, halofantrine, pimozide, derivati t'ergot).
English: Consequently, for patients concomitantly taking strong CYP3A4 or CYP2C19 inhibitors the recommended dose is 50 mg twice daily (see section
Maltese: Bħala konsegwenza, għall-pazjenti li qed jieħdu wkoll inibituri qawwija ta' CYP3A4 jew CYP2C19 id-doża rrakkomandata hija ta' 50 mg darbtejn kuljum (ara sezzjoni 4.2).
English: No measurable amount of unchanged cilostazol is excreted in the urine, and less than 2% of the dose is excreted as the dehydro-cilostazol metabolite.
Maltese: L-ebda ammont mkejjel ta' cilostazol mhux mibdul ma ġie eliminat flawrina, u anqas minn 2% tad-doża titneħħa bħala l-metabolit dehydro-cilostazol.
English: Before you start taking <Cilostazol-containing medicinal product>, please tell your doctor if you are taking: erythromycin, clarithromycin or rifampicin (antibiotics) ketoconazole (to treat fungal infections) omeprazole (to treat excess acid in the stomach) diltiazem (to treat high blood pressure or chest pain) cisapride (to treat stomach disorders) lovastatin, simvastatin or atorvastatin (to treat high cholesterol in the blood) halofantrine (to treat malaria) pimozide (to treat mental illnesses) ergot derivatives (to treat migraine, e.g. ergotamine, dihydroergotamine) carbamazepine or phenytoin (to treat convulsions)
Maltese: <Prodott mediċinali li fih cilostazol> huwa għall-użu sekondarju, f'pazjenti li għalihom modifiki fl-istil tal-ħajja (inkluż waqfien mit-tipjip u programmi ta' eżerċizzju [issorveljati]) u interventi xierqa oħra naqsu li jtejbu biżżejjed is-sintomi ta' klawdikazzjoni intermittenti tagħhom.
English: In such cases, a cilostazol dosage of 50 mg twice daily is recommended (see section 4.5 for further information).
Maltese: F'każijiet bħal dawn, dożaġġ ta' cilostazol ta' 50 mg darbtejn kuljum huwa rrakkomandat (ara sezzjoni 4.5 għal aktar informazzjoni).
English: Most patients recovered on discontinuation of cilostazol.
Maltese: Tiħux <Prodott mediċinali li fih cilostazol>
English: The dehydro metabolite, which has 4-7 times the potency of cilostazol in inhibiting platelet aggregation, appears to be formed primarily via CYP3A4.
Maltese: Il-metabolit deidro, li għandu 4-7 darbiet il-qawwa ta' cilostazol biex jimpedixxi l-aggregazzjoni tal-plejtlits, jidher li jiġi ffurmat prinċipalment permezz ta' CYP3A4.
English: Since cilostazol is extensively metabolised by hepatic enzymes, it is contraindicated in patients with moderate or severe hepatic impairment.
Maltese: Peress li cilostazol jiġi metabolizzat b'mod estensiv minn enżimi epatiċi, huwa kontraindikat f'pazjenti b'indeboliment epatiku moderat jew sever.
English: In total, 1,439 patients with intermittent claudication and no heart failure have been treated with cilostazol or placebo for up to three years.
Maltese: B'kollox, 1,439 pazjent b'klawdikazzjoni intermittenti u mingħajr ebda insuffiċjenza tal-qalb kienu kkurati b'cilostazol jew plaċebo għal massimu ta' tliet snin.
English: Cilostazol also inhibits smooth muscle cell proliferation in rat and human smooth muscle cells in vitro, and inhibits the platelet release reaction of platelet-derived growth factor and PF-4 in human platelets.
Maltese: Cilostazol jimpedixxi wkoll il-profilerazzjoni taċ-ċelluli muskolari melliesa fil-firien u ċ-ċelluli muskolari melliesa fil-bniedem in vitro, u jimpedixxi r-reazzjoni ta' rilaxx tal-plejtlits tal-fattur ta' żvilupp derivat minn plejtlits u PF-4 fil-plejtlits tal-bniedem.
English: Paresis, hypoaesthesia
Maltese: Reazzjoni allerġika
English: The most commonly reported adverse reactions in clinical trials were headache (in > 30%), diarrhoea and abnormal stools (in > 15% each).
Maltese: Ir-reazzjonijiet avversi l-aktar komunement irrappurtati fi provi kliniċi kienu uġigħ ta' ras (f'> 30%), dijarea u ppurgar anormali (f'> 15% kull wieħed).
English: How to store <Cilostazol-containing medicinal product> Contents of the pack and other information
Maltese: Kif taħżen <Prodott mediċinali li fih cilostazol> Kontenut tal-pakkett u informazzjoni oħra
English: Ecchymosis
Maltese: FARMAĊEWTIKU
English: In a clinical study in healthy subjects, cilostazol given 150mg b.i.d.
Maltese: INFORMAZZJONI BIL-BRAILLE <Prodott mediċinali li fih cilostazol> 50 mg
English: Cilostazol and several of its metabolites are phosphodiesterase III inhibitors which suppress cyclic AMP degradation, resulting in increased cAMP in a variety of tissues including platelets and blood vessels.
Maltese: Cilostazol u diversi metaboliti tiegħu huma impedituri ta' phosphodiesterase li jrażżnu ddegradazzjoni AMP ċikliku, li jirriżulta f'żieda f'cAMP f'diversi tessuti li jinkludu plejtlits u vażi tad-demm.
English: A randomized, double-blind, placebo-controlled Phase IV study was conducted to assess the long-term effects of cilostazol, with focus on mortality and safety.
Maltese: IV, double-blind, bil-plaċebo bħala kontroll sar biex jassessja l-effetti fuq tul ta' żmien ta' cilostazol, bil-miri jkunu l-mortalità u s-sigurtà.
English: If a patient is to undergo elective surgery and antiplatelet effect is not necessary, cilostazol should be stopped 5 days prior to surgery.
Maltese: Jekk pazjent għandu jgħaddi minn kirurġija elettiva u l-effett kontra l-plejtlits mhux meħtieġ, cilostazol għandu jitwaqqaf 5 ijiem qabel il-kirurġija.
English: After 12 weeks, as compared to placebo, <Cilostazol-containing medicinal product> 100 mg b.i.d.
Maltese: < Läkemedel som innehåller cilostazol > 100 mg tabletter
English: Refer also to section 4.8.
Maltese: Irreferi wkoll għal sezzjoni 4.8.
English: changes in the blood pressure decrease in red cells, white cells and platelets in your blood difficulty breathing difficulty moving fever hot flushes eczema and other skin rashes reduced sensation of the skin runny or sticky eyes (conjunctivitis) ringing in the ears (tinnitus) liver problems including hepatitis changes in the urine
Maltese: Studji ta' mutaġeniċità kienu negattivi għal mutazzjoni tal-ġeni batteriċi, reparazzjoni ta' DNA batterika, mutazzjoni mammiferi tal-ġeni ċellulari u aberrazzjonijiet kromosomali talmudullun in vivo tal-ġurdien.Fit-testijiet in vitro fuq ċelluli tal-ovarji tal-ħemster Ċiniż cilostazol ipproduċa żieda dgħajfa iżda sinifikanti fil-frekwenza t'anormalitajiet filkromożomi.
English: Following 24 weeks treatment, cilostazol 100 mg b.i.d.
Maltese: <Prodott mediċinali li fih cilostazol> 100 mg [Biex timtela mill-pajjiż partikolari]
English: A higher rate of haemorrhage was observed with the concomitant use of clopidogrel, ASA and cilostazol in the CASTLE trial.
Maltese: L-effetti sekondarji li ġejjin ġew rappurtati għal <Prodott mediċinali li fih cilostazol>.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains 50 mg of cilostazol.
Maltese: < Médicament contenant du cilostazol > 50 mg comprimé
English: INFORMATION IN BRAILLE
Maltese: Informazzjoni għall-utent
English: What <Cilostazol-containing medicinal product> looks like and contents of the pack The <Cilostazol-containing medicinal product> 50 mg tablet is a white, round, flat-faced tablet, debossed with “OG31” on one side.
Maltese: Kif jidher <Prodott mediċinali li fih cilostazol> u l-kontenut tal-pakkett Il-pillola ta' 50 mg ta' <Prodott mediċinali li fih cilostazol> hija pillola bajdanija, tonda, b'wiċċ ċatt, imnaqqxa b'“OG31” fuq naħa waħda.
English: The <Cilostazol-containing medicinal product> 100 mg tablet is a white, round, flat-faced tablet, debossed with “OG30” on one side.
Maltese: Il-pillola ta' 100 mg ta' <Prodott mediċinali li fih cilostazol> hija bajdanija, tonda, b'wiċċ ċatt, mnaqqxa b'"OG30" fuq naħa waħda.
English: No dose adjustment is necessary in patients with a creatinine clearance of > 25 ml/min.
Maltese: • Indeboliment tal-kliewi sever: tneħħija tal-kreatinina ta'  25 ml/min
English: The apparent elimination half-life of cilostazol is 10.5 hours.
Maltese: Il-half-life tal-eliminazzjoni apparenti ta' cilostazol hi 10.
English: This summary was last updated in March 2016.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'Marzu 2016.
English: Profender emodepside / praziquantel
Maltese: Profender emodepside / prażikwantel
English: The full EPAR for Profender can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: The two active substances in Profender interact with different parts of the parasites systems.
Maltese: Iż-żewġ sustanzi attivi fi Profender jinteraġixxu ma' partijiet differenti tas-sistemi tal-parassiti.
English: This is a summary of the European public assessment report (EPAR) for Profender.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Profender.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom bottle for use only in a veterinary surgery, where the vet will measure the exact volume of Profender needed for each cat before application.
Maltese: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
English: Profender is an antiparasitic medicine that contains two active substances, emodepside and praziquantel.
Maltese: Profender huwa mediċina kontra l-parassiti li fiha żewġ sustanzi attivi, l-emodepside u l-prażikwantel.
English: Why is Profender approved?
Maltese: Għal xiex ġiet approvat Profender?
English: The laboratory study showed Profender to reduce the worm count in the lungs by more than 99%.
Maltese: L-istudju fil-laboratorju wera li Profender inaqqas l-għadd ta' ħniex fil-pulmun b'aktar minn 99%.
English: The European Commission granted a marketing authorisation valid throughout the EU for Profender on 27 July 2005.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha għal Profender fist27 ta' Lulju 2005.
English: In each of the field studies, animals of various breeds, age groups and different weights that were naturally infected with roundworms or tapeworms in their guts, were treated either with Profender or another approved worming medicine (selamectin in cats, and milbemycin oxime and praziquantel in dogs).
Maltese: F'kull wieħed mill-istudji li saru fuq il-post, annimali ta' razez varji, gruppi ta' etajiet u piżijiet differenti ġew infettati b'mod naturali minn ħniex u dud f'imsarinhom, ġew ikkurati bi Profender jew b'mediċina oħra tal-ħniex (selamectin fil-qtates, u milbemycin oxime u prażikwantel fil-klieb)..
English: For lungworms in cats a laboratory study together with a field study showed Profender to reduce the number of larvae passed in the animal's faeces by more than 99%.
Maltese: Għal-lungworms fil-qtates, studju fil-laboratorju flimkien ma' studju fuq il-post urew li Profender inaqqas l-għadd ta' larva eliminata mal-feċi tal-annimal b'aktar minn 99%.
English: Mild and short-lived signs relating to the nervous system such as ataxia (inability to co-ordinate muscle movements) or tremor (shaking) may occur in very rare cases.
Maltese: F'każijiet rari ħafna jista' jkun hemm sinjali ħfief u temporanji marbuta mas-sistema nervuża bħal atassja (inkapaċità li tikkoordina l-movimenti tal-muskoli) jew rogħda (tregħid).
English: Profender should not be used in young animals (cats under 8 weeks of age or weighing less than 0.5 kg, or puppies under 12 weeks of age or weighing less than 1 kg).
Maltese: Profender ma għandux jintuża fuq anninali ta' età żgħira (qtates iżgħar minn 8 ġimgħat jew li jiżnu inqas minn 0.5 kg, jew ġriewi iżgħar minn 12-il ġimgħa jew li jiżnu inqas minn 1 kg).
English: What is Profender?
Maltese: X'inhu Profender?